Atrial fibrillation and anticoagulant treatment in end – stage renal disease patients. where do we stand

The frequent coexistence in daily clinical practice of chronic kidney disease (CKD) and atrial fibrillation (AF), especially in the elderly, represents a conundrum for physicians, mainly related to the management of anticoagulant therapy. The reduction of estimated glomerular filtration rate (eGFR) impairs anticoagulant clearance, increasing bleeding propensity. Moreover, dysfunctional responses of endothelial cells and inflammatory systems both trigger thromboembolic status. Those mechanisms pose AF patients with CKD to increased risk of adverse events. If several evidences suggested the use of direct oral anticoagulants (DOACs) over warfarin as preferred anticoagulant strategy in patients with moderate to severe CKD (eGFR> 30 ml/min), less is known about the optimal anticoagulation management in patients with end-stage renal disease (ESRD) or on renal replacement therapy (RRT). Furthermore, a pivotal feature to be considered when choosing the anticoagulant drug in CKD patients is represented by nephroprotective capability. Indeed, anticoagulant therapy with warfarin showed detrimental effects on kidney function, whereas DOACs demonstrated a beneficial effect on renal function preservation. Mounting evidences showed that, when pharmacological treatment cannot be pursued due to contraindication to anticoagulation, left atrial appendage occlusion (LAAO) may represent a valid alternative. This brief review outlines the current evidence regarding anticoagulation therapy in ESRD/...
Source: Cardiorenal Medicine - Category: Urology & Nephrology Source Type: research